Inve US ▾
BBBBIO

BridgeBio Pharma (BBIO) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 10, 2026

Source: earnings call transcript

Executive summary

BridgeBio Pharma, Inc. Q2 FY26 — Attruby Growth and Pipeline Advancement

BridgeBio Pharma reported a strong Q2 FY26, driven by continued commercial momentum for Attruby, which saw significant growth in the treatment-naive segment and new clinical differentiation data. The company also advanced all three late-stage pipeline programs into regulatory review, securing priority designations for two, and bolstered its financial position with a $1 billion equity financing. While the Attruby switch market normalizes and combination therapy for ATTR-CM faces setbacks, BridgeBio is poised for multiple product launches and sustained growth, focusing on clinical differentiation and expanding market reach.

Highlights

5

  • Attruby net product revenue grew to $222.4 million, marking over $35 million sequential sales increase.

  • Attruby demonstrated continued commercial momentum, being the fastest-growing brand in its space at 23% this quarter.

  • All three late-stage pipeline programs (LGMD2I, ADH1, achondroplasia) moved into regulatory review, with LGMD2I and ADH1 receiving priority review and the first PDUFA date set for November 27.

  • Completed a $1 billion preferred equity financing on July 1, 2026, increasing cash balance to approximately $1.7 billion.

  • Observed the first evidence of direct kidney protection for Attruby in ATTR-CM, with a hazard ratio of 0.42 for all-cause mortality or cardiovascular-related hospitalization in patients with acute eGFR dips.

Concerns

3

  • The second-line/switch segment for Attruby is settling into a lower, more normalized steady state after forced VYNDAQEL switching largely worked through.

  • The CARDIO-TTRansform study for eplontersen in ATTR cardiomyopathy did not meet its primary efficacy endpoint, suggesting no benefit from combination therapy.

  • License and services revenue decreased to $5.8 million from $37.4 million in Q2 FY25, primarily due to a one-time $30 million regulatory milestone in the prior year.

Guidance & targets

CategoryTargetConfidence
Worldwide sales of acoramidis
blockbuster status
high materiality
High
Infigratinib NDA acceptance and priority review
Q4 of 2026
high materiality
Medium
Infigratinib approval
mid-2027
high materiality
Medium
RECLAIM-HP trial readout
in the next 18 months
medium materiality
High
GondolaBio INDs
5 additional INDs
low materiality
High
GondolaBio clinical proof-of-concept readouts
8 clinical proof-of-concept readouts
low materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
ATTR Cardiomyopathy
Attruby is the fastest-growing brand in the space, driven by the treatment-naive segment. The switch segment is normalizing. New clinical data reinforces differentiation, including kidney protection and real-world evidence showing outperformance against tafamidis.
Brand growth: 23%Overall market growth: 19%Overall market growth YoY: 51%Frontline share growth: 2-3 percentage pointsGross to net: 30% to 40%Reduction in composite cardiovascular events vs tafamidis: 37%Reduction in hospitalizations vs tafamidis: 34%Reduction in diuretic intensification, heart failure hospitalization and mortality vs VYNDAMAX: 34%Hazard ratio for all-cause mortality or cardiovascular-related hospitalization (Attruby vs placebo with acute eGFR dips): 0.42Hazard ratio for cardiovascular-related hospitalization alone (Attruby vs placebo with acute eGFR dips): 0.34
$222.4 million—$35 million or more sequential sales increase—
International
Royalty revenue primarily earned from net product sales of Beyonttra in the EU and Japan.
$15.4 millionincreased from $1.6 million——

Deals & partnerships

Sixth Street with participation from HealthCare Royalty Preferred equity investment $1 billion

Closed on July 1, 2026.

Risks & headwinds

Normalization of Attruby's second-line/switch market post-18 months launch

settling into a lower and more normalized steady state

Mitigation:Continued first-line strength and focus on clinical differentiation.

CARDIO-TTRansform study failure for eplontersen Q2 FY26

did not meet its primary efficacy endpoint with no benefit observed with combination therapy

Mitigation:Reinforces stabilization as first-line standard of care, positioning Attruby favorably as a near-complete stabilizer.

Competitive pricing pressure in ATTR cardiomyopathy market ongoing

Pfizer's net price erosion from new payer contracts

Mitigation:Focus on clinical differentiation, not chasing competitor rebates; belief that long-term access will be at parity and clinical differentiation will win.

What to watch in Q3 FY26

Attruby frontline growth

coming 12 to 18 months
Current 2-3 percentage points share growth in frontline
Target continued aggressive growth

Why it matters

Indicates sustained market penetration and adoption of Attruby as the preferred stabilizer.

I mean, my expectation would be that we really hit a positive second derivative here and continue to grow pretty aggressively in the front line over the coming 12 to 18 months, but let's see.

Find out whether BBIO delivers this. Inve re-checks your case every morning.

Q&A highlights

What drives Attruby's first-line consistency and durability, especially given competitive developments? How will CARDIO-TTRansform failure and upcoming ESC data impact Attruby's treatment-naive share?

Attruby's performance is rooted in its clinical differentiation (early separation, hospitalization reduction). New real-world evidence, kidney data, and CARDIO-TTRansform results will further enhance this. Stabilizer frontline will likely gain from CARDIO-TTRansform data, making the pool larger. Management expects a "positive second derivative" and aggressive growth in the frontline over the next 12-18 months.

“I mean, my expectation would be that we really hit a positive second derivative here and continue to grow pretty aggressively in the front line over the coming 12 to 18 months, but let's see.”

asked by Tyler Van Buren · answered by Neil Kumar

2 min read 7 chapters

Detailed narrative

Attruby Commercial Momentum and Differentiation

Attruby demonstrated strong commercial momentum in Q2 FY26, growing 23% and being the fastest-growing brand in its space. This growth was primarily driven by the treatment-naive segment, with new patient starts consistent with Q1. The company expects continued first-line market growth and aims to increase its share, supported by expanding clinical differentiation data, including real-world evidence and newly documented renal protective effects.

Kidney Protective Effects of Attruby

New data published in Circ: Heart Failure showed Attruby driving the first-ever early and sustained direct kidney protective effects in ATTR cardiomyopathy, including eGFR slope improvement and urinary albumin-to-creatinine ratio reduction. This effect, which mirrors early clinical outcomes, suggests Attruby may protect both heart and kidney simultaneously. Intriguingly, acute eGFR dips on Attruby were associated with better outcomes (HR 0.42 for all-cause mortality/CV hospitalization), contrasting with placebo, and the company plans further studies in orphan kidney indications.

Impact of CARDIO-TTRansform Results

The failure of the CARDIO-TTRansform study for eplontersen to meet its primary efficacy endpoint reinforced stabilization as the first-line standard of care for ATTR cardiomyopathy. BridgeBio believes this outcome strengthens the case for stabilizers first, particularly for Attruby as a near-complete stabilizer, and may position it favorably in the second-line setting if monotherapy knockdown continues to underperform.

Late-Stage Pipeline Advancements

All three late-stage programs—BBP-418 for LGMD2I, encaleret for ADH1, and infigratinib for achondroplasia—have advanced into regulatory review. BBP-418 and encaleret received priority review from the FDA, with PDUFA dates set for November 27, 2026, and May 8, 2027, respectively. Infigratinib's NDA was submitted following positive Phase III results published in The New England Journal of Medicine, targeting mid-2027 approval.

Encaleret's Broader Opportunity in Chronic Hypoparathyroidism

Beyond ADH1, encaleret is being developed for chronic hypoparathyroidism (CHP), a condition affecting 200,000 patients in the U.S. and EU. Management believes this opportunity is overlooked, citing the need for an oral option that corrects both hypocalcemia and hypercalciuria, and addresses PTH-mediated bone issues. The RECLAIM-HP Phase III trial has commenced screening, with results expected in 18 months, offering a potential blockbuster opportunity.

Infigratinib's Differentiation in Achondroplasia

Infigratinib, an oral FGFR3-targeted therapeutic for achondroplasia, offers a significant advantage over injectable competitors due to its convenient once-daily capsule formulation. It also demonstrated functional differentiation in Phase III, including a statistically significant 0.37 standard deviation improvement in arm span, the first placebo-controlled benefit of its kind. The company anticipates achieving over 65% peak market share in this space.

Financial Position and Capital Allocation

BridgeBio closed a $1 billion preferred equity investment, bringing its cash, cash equivalents, and marketable securities to approximately $1.7 billion as of July 1, 2026. This capital provides a significant runway to fund operating activities, support the three upcoming launches, and continue investing in Attruby's commercial growth while maintaining financial discipline.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.